128 completed, 35 terminated, 10 unknown, 9 withdrawn. 63 Phase 3, 46 Phase 2, 33 Phase 1, 23 Phase 4, 7 Not applicable.
Follow Actelion: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Pilot Randomized Trial of Ambulatory Exercise in Pulmonary Hypertension Usual Care, Home-based exercise program - Pulmonary Arterial Hypertension | Not applicable | Withdrawn | University of Michigan | 2024-08-11 | 2024-08-14 | |
| A Study of Macitentan in Children Below 2 Years of Age Macitentan - Arterial Hypertension, Pulmonary | Phase 1 | Withdrawn | Actelion | 2024-03-14 | 2025-03-30 | |
| A Study of Two Macitentan Formulations in Healthy Adult Participants Macitentan - Healthy | Phase 1 | Completed | Actelion | 28 | 2022-06-22 | 2025-03-30 |
| A Study of Single and Multiple Doses of Different Formulations of a Prostacyclin Receptor Agonist Prostacyclin Receptor Agonist - Pulmonary Arterial Hypertension | Phase 1 | Completed | Actelion | 88 | 2022-06-21 | 2025-03-30 |
| A Study of Two Different Test Formulations Compared to the Reference Formulation of Macitentan in Healthy Adult Participants Macitentan - Healthy | Phase 1 | Completed | Actelion | 23 | 2022-05-25 | 2025-03-30 |
| A Study Providing Treatment Access in Participants With Pulmonary Hypertension Completing a Parent Study and Having no Other Option Macitentan, Selexipag, Macitentan/Tadalafil FDC - Hypertension, Pulmonary | Phase 3 | Recruiting | Actelion | 280 | 2022-05-04 | 2026-11-03 |
| A Study of Fixed Dose Combination of Macitentan/Tadalafil (10 mg/20 mg) Compared to the Reference Free Combination of Macitentan and Tadalafil in Healthy Adult Participants Macitentan 10 mg, Tadalafil 20 mg, Macitentan 10 mg/Tadalafil 20mg FDC - Healthy | Phase 1 | Completed | Actelion | 40 | 2022-02-04 | 2025-03-30 |
| A Study of Real-world Cohort of Pulmonary Arterial Hypertension (PAH) Participants PAH Therapies - Pulmonary Arterial Hypertension | Phase 4 | Terminated | Actelion | 232 | 2021-10-14 | 2025-02-03 |
| A Study of Two Macitentan Pediatric Formulations in Healthy Adult Participants Macitentan - Healthy | Phase 1 | Completed | Actelion | 16 | 2021-07-08 | 2025-03-30 |
| A Study of Selexipag Assessing Right Ventricular Remodeling in Pulmonary Arterial Hypertension by Cardiac Magnetic Resonance Imaging JNJ-67896049 - Pulmonary Arterial Hypertension | Phase 4 | Terminated | Actelion | 9 | 2021-07-07 | 2025-03-30 |
| A Study of Selexipag in Participants Who Participated in a Previous Selexipag Study Selexipag - Hypertension, Pulmonary | Phase 3 | Completed | Actelion | 43 | 2021-05-03 | 2025-05-01 |
| A Study in Participants With Sarcoidosis-associated Pulmonary Hypertension (SAPH) to Assess the Efficacy and Safety of Oral Selexipag Selexipag, Placebo - Sarcoidosis-associated Pulmonary Hypertension | Phase 2 | Terminated | Actelion | 10 | 2021-02-26 | 2024-05-08 |
| Assessing the Repeatability of NT-proBNP Testing Using Laboratory and Point of Care Testing in PAH Exercise group - Pulmonary Artery Hypertension | Completed | Sheffield Teaching Hospitals NHS Foundation Trust | 40 | 2021-02-19 | 2023-08-14 | |
| A Study for the Identification of Biomarker Signatures for Diagnosis of Pulmonary Hypertension (PH) in Participants at Low or Intermediate Probability of PH Undergoing Cardiac Magnetic Resonance Imaging Blood Sample, Cardiac MRI - Hypertension, Pulmonary | Early Phase 1 | Completed | Actelion | 86 | 2020-12-11 | 2025-03-30 |
| A Study to Evaluate Efficacy and Safety of Macitentan 75 mg in Inoperable or Persistent/Recurrent Chronic Thromboembolic Pulmonary Hypertension Macitentan, Placebo - Chronic Thromboembolic Pulmonary Hypertension | Phase 3 | Terminated | Actelion | 127 | 2020-07-07 | 2025-06-27 |
| Outcome Study Assessing a 75 Milligrams (mg) Dose of Macitentan in Patients With Pulmonary Arterial Hypertension Macitentan 10 mg, Macitentan 37.5 mg, Macitentan 75 mg - Pulmonary Arterial Hypertension | Phase 3 | Active not recruiting | Actelion | 935 | 2020-06-30 | 2026-11-03 |
| Safety and Efficacy of Miglustat in Chinese NPC Patients Miglustat - Niemann-Pick Disease, Type C | Phase 4 | Completed | Actelion | 17 | 2020-04-02 | 2025-03-30 |
| A Study of Selexipag in Healthy Male Participant Selexipag matrix tablet, Selexipag encapsulated pellets, Selexipag Immediate-release (IR) tablet - Healthy | Phase 1 | Completed | Actelion | 24 | 2020-01-23 | 2025-03-30 |
| A Study of Selexipag as Add-On Treatment to Standard of Care in Children With Pulmonary Arterial Hypertension Selexipag, Placebo, Standard of Care (SOC): Endothelin receptor antagonist - Hypertension, Pulmonary | Phase 3 | Active not recruiting | Actelion | 138 | 2020-01-16 | 2026-11-03 |
| A 2-part Study to Investigate the Effect of Macitentan in Healthy Male Participants Macitentan, Sildenafil, Riociguat - Healthy | Phase 1 | Completed | Actelion | 47 | 2020-01-14 | 2025-03-30 |
Showing 20 of 188. Sign in to see all of them.
Pulmonary Arterial Hypertension (66) · Hypertension, Pulmonary (38) · Scleroderma, Systemic (12) · Idiopathic Pulmonary Fibrosis (8) · Eisenmenger Complex (6) · Heart Defects, Congenital (6) · digital ulcers (6) · Clostridium Infections (5) · Lung Diseases, Interstitial (5) · Multiple Sclerosis (5) · Scleroderma, Diffuse (5) · Anemia, Sickle Cell (4) · Hypertension (4) · Motor Activity (4) · Cystic Fibrosis (3)
macitentan (46) · Bosentan (44) · selexipag (22) · Iloprost (16) · ponesimod (12) · miglustat (10) · Epoprostenol (5) · Tadalafil (5) · cadazolid (5) · Vancomycin (4) · Amines (3) · Moxifloxacin (3) · Sildenafil Citrate (3) · Tablets (3) · Observation (2)
United States (81) · Germany (53) · France (49) · United Kingdom (43) · Canada (36) · Spain (35) · Poland (33) · Belgium (31) · Italy (31) · Russia (30) · Hungary (28) · Austria (27) · Czechia (25) · Israel (24) · Australia (23)
Andjela Kusic-Pajic, MD (3) · Gary Palmer, MD, MBA (3) · Michael Landzberg, MD (3) · Patrick Brossard, PhD (3) · Shirin Bruderer, PhD (3) · Aline Frey (2) · Anne Claire Marrast, MD (2) · Isabelle Leconte (2) · James D Anholm, MD (2) · Laila Rouault, MD (2) · Loic Perchenet, PhD (2)
PMID 20175775, PMID 27163986, PMID 29447737, PMID 29501590, PMID 29680101, PMID 30709665, PMID 31109190, PMID 33765691, PMID 34727317, PMID 35819570, PMID 38184507, PMID 38451426, PMID 39520648, PMID 39585521, PMID 40066571, PMID 40388087, PMID 41258625, PMID 42023995, PMID 17901413, PMID 18572079, PMID 18977464, PMID 19095129, PMID 19595619, PMID 19679600, PMID 20002090, PMID 20350333, PMID 20506355, PMID 20507945, PMID 20558556, PMID 20585012, PMID 20705534, PMID 20805294, PMID 21282484, PMID 21393391, PMID 21474646, PMID 21680644, PMID 21757572, PMID 21778257, PMID 22086881, PMID 22127844, PMID 22200728, PMID 22281797, PMID 22362844, PMID 22661451, PMID 22883740, PMID 23270487, PMID 23348820, PMID 23370599, PMID 23429998, PMID 23598723
2016 (6), 2019 (6), 2018 (4), 2009 (2), 2015 (2), 2017 (2), 2004 (1), 2005 (1), 2014 (1), 2023 (1)